0 followers
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being eva... Read more
Andrew Cheng
Kyverna Therapeutics
7 followers
Generate Biomedicines
3 followers
Kriya Therapeutics
1 follower
Gameto
4 followers
Synthekine
3 followers
Tango Therapeutics
2 followers
Caribou Biosciences
2 followers
Vera Therapeutics
2 followers
Neogene Therapeutics
2 followers
Day One Biopharmaceuticals
1 follower
Apogee Therapeutics
1 follower
Explore companies